RESEARCH PEPTIDE FUNDAMENTALS / COLOPHON
Contact the Editorial Desk
Correspondence on citations, corrections, and newly published research — the things a reference desk is actually useful to hear about.
Editorial correspondence
The survey takes corrections seriously: a citation quoted inaccurately, a trial that has since published fresh results, a regulatory status update, or a peer-reviewed study on any of the five compounds that belongs on the references page. This is the single most useful kind of message it receives, and every one is read.
The quickest-actioned notes name the exact page, quote the exact passage at issue, and attach a supporting reference — a DOI or PubMed identifier where possible — so the change can be checked against its source before anything is edited.
Editorial mailbox: editors@researchpeptidesus.com
Outside the survey
So no message goes unanswered for the wrong reason: Research Peptides US is a literature survey, not a clinical service or a seller. It cannot advise on human use of any compound here, suggest a dose or schedule for anyone, judge whether a cited trial applies to a specific person, or sell, source, or help locate any compound from any supplier. It cannot advise athletes on anti-doping status either.
Tirzepatide is a prescription medicine. Retatrutide is investigational and not legally available outside clinical trials. BPC-157 and KPV are unregulated research chemicals with no approved human use. Readers seeking medical guidance should consult a licensed clinician. Replies to editorial correspondence are not guaranteed and may be delayed.